The Drug Enforcement Administration (DEA) issued three permits in December to Royal Emerald Pharmaceuticals (REP) for cultivation, research, development, and manufacturing of medicines derived from cannabis and other botanicals.
REP says it the first-of-its-kind cannabis pharmaceutical company in the United States to hold all four licenses.
DEA issued the manufacturing, analytical lab, and import licenses in December following an earlier license for distribution.
DEA’s recent step shows that the government is easing its hold on cannabis cultivated for research reasons. It took a long time for cannabis companies to get DEA permission, but it eventually happened.
“We are excited and very happy to receive these DEA licenses for cannabis research,” says REP CEO Mark Crozier. “This news is huge and comes with immense responsibilities—we have been chosen to provide researchers and universities with high quality cannabis so they can move forward with their research projects. These researchers have struggled for decades to be recognized by the medical and scientific communities. Now they can.”
REP’s primary campus is a 100,000 square foot facility on Palm Drive in Desert Hot Springs.
The company expects to recruit 250 people for the growth and research center in early 2022 and up to a possible 1,000 after phase two.
RapidGrow To Join The Development Process
REP partner RapidGrow LED Technologies, Inc., the nation’s largest integrated manufacturing and LED lighting tech firm, will watch and gather plant development parameters.
The company’s open architecture and completely wireless connectivity system will collect data and provide essential growth indicators like temperature, humidity, PAR, CO2, soil moisture, HVAC, and vapor pressure deficit for REP and DEA.
“Rapidgrow is proud to partner with REP on such a historic and significant mission to support medical research projects with the most advanced indoor grow lighting technology,” says RapidGrow CRO and President Bryan Fried. “We’re confident PANGEA and RapidGrow LED fully customizable light installations will provide REP researchers and the DEA with data and automation grow features to truly transform how we treat our veterans, law enforcement, and first responders.”
REP aims to dominate the cannabis pharmaceutical market by developing innovative treatments for people with severe pain, opioid abuse, PTSD, anxiety, depression, sleep problems, and other life-threatening conditions.
Crozier says that veterans and first rescuers pay “a tremendous price” for our benefit. He says he is dedicated to delivering patients with safe, effective, and non-addictive medicines.
He added that Royal Emerald Pharmaceuticals seeks the most up-to-date, innovative, and industry-approved research to secure its standing as the leader in the rapid-paced, dynamic market.
Crozier says REP will deliver cutting-edge THC and CBD medications and active medicinal components to DEA licensees, researchers, colleges, institutions, government agencies, and the Veterans Administration (VA).
“We adhere to the highest standards and quality measures in our labs to ensure that our products exceed consumer expectations,” says Crozier. “We guarantee superior quality medicines by complying with current Good Manufacturing Practices (cGMP) established by the Food and Drug Administration (FDA). Our scientists and team of experts are experienced in drug research and development, ensuring our products are consistent, pure and safe for consumers.”